nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—Ceruletide—CCKAR—pancreatic cancer	0.0343	1	CrCbGaD
Degarelix—GNRHR—Peptide GPCRs—SSTR3—pancreatic cancer	0.0129	0.0426	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—SSTR1—pancreatic cancer	0.0124	0.0408	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—SSTR2—pancreatic cancer	0.0119	0.0393	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—CCKBR—pancreatic cancer	0.0115	0.0379	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—SSTR2—pancreatic cancer	0.0101	0.0333	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—CCKBR—pancreatic cancer	0.00973	0.0321	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—CCKAR—pancreatic cancer	0.00856	0.0283	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—AGTR1—pancreatic cancer	0.00576	0.019	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—CCKBR—pancreatic cancer	0.00547	0.0181	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—CNR1—pancreatic cancer	0.00529	0.0175	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKBR—pancreatic cancer	0.00489	0.0162	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.00478	0.0158	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GAST—pancreatic cancer	0.0047	0.0155	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—CCK—pancreatic cancer	0.00425	0.0141	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.00421	0.0139	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.00408	0.0135	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00407	0.0134	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.0039	0.0129	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.00382	0.0126	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.00381	0.0126	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.00375	0.0124	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.00365	0.012	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PRLHR—pancreatic cancer	0.00364	0.012	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.00362	0.012	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—SSTR3—pancreatic cancer	0.0031	0.0102	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—SSTR1—pancreatic cancer	0.00297	0.0098	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PPY—pancreatic cancer	0.00291	0.00961	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GCG—pancreatic cancer	0.00287	0.00949	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—SSTR2—pancreatic cancer	0.00286	0.00944	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00282	0.00931	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCKBR—pancreatic cancer	0.00276	0.00911	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.00275	0.00907	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—AGTR1—pancreatic cancer	0.00274	0.00905	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.0027	0.00892	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.00257	0.00849	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—pancreatic cancer	0.00245	0.0081	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—SCT—pancreatic cancer	0.00225	0.00743	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCK—pancreatic cancer	0.00215	0.00709	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.00214	0.00705	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CNR2—pancreatic cancer	0.00209	0.00691	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GLP1R—pancreatic cancer	0.00209	0.00691	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCKAR—pancreatic cancer	0.00206	0.00679	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.00197	0.00651	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—SHH—pancreatic cancer	0.00188	0.00619	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PRLHR—pancreatic cancer	0.00187	0.00617	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—IAPP—pancreatic cancer	0.00185	0.00612	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.00182	0.006	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PTHLH—pancreatic cancer	0.00178	0.00587	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PTCH1—pancreatic cancer	0.00178	0.00587	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—SSTR3—pancreatic cancer	0.00175	0.00578	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GDI1—pancreatic cancer	0.00171	0.00566	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GDI2—pancreatic cancer	0.00171	0.00566	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—SSTR1—pancreatic cancer	0.00168	0.00554	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PPY—pancreatic cancer	0.00164	0.00543	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—SST—pancreatic cancer	0.00163	0.00537	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—SSTR2—pancreatic cancer	0.00161	0.00533	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—SSTR3—pancreatic cancer	0.00159	0.00525	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCKBR—pancreatic cancer	0.00156	0.00515	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—SSTR1—pancreatic cancer	0.00152	0.00503	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CNR1—pancreatic cancer	0.0015	0.00496	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PPY—pancreatic cancer	0.00149	0.00493	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—SSTR2—pancreatic cancer	0.00147	0.00484	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GCG—pancreatic cancer	0.00145	0.00479	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCKBR—pancreatic cancer	0.00142	0.00468	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—AGTR1—pancreatic cancer	0.00138	0.00457	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GAST—pancreatic cancer	0.00134	0.00443	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—SCT—pancreatic cancer	0.00127	0.0042	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GAST—pancreatic cancer	0.00122	0.00402	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCK—pancreatic cancer	0.00121	0.004	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GLP1R—pancreatic cancer	0.00118	0.0039	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CNR2—pancreatic cancer	0.00118	0.0039	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCKAR—pancreatic cancer	0.00116	0.00384	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—SCT—pancreatic cancer	0.00115	0.00381	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PRLHR—pancreatic cancer	0.0011	0.00365	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCK—pancreatic cancer	0.0011	0.00364	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CNR2—pancreatic cancer	0.00107	0.00354	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GLP1R—pancreatic cancer	0.00107	0.00354	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCKAR—pancreatic cancer	0.00106	0.00349	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IAPP—pancreatic cancer	0.00105	0.00346	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ZNRF3—pancreatic cancer	0.00104	0.00343	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ACVR1B—pancreatic cancer	0.00104	0.00343	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PTHLH—pancreatic cancer	0.001	0.00332	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—SHH—pancreatic cancer	0.000963	0.00318	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IAPP—pancreatic cancer	0.000951	0.00314	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SSTR3—pancreatic cancer	0.000939	0.0031	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—DTX1—pancreatic cancer	0.000939	0.0031	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—SST—pancreatic cancer	0.000919	0.00304	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTHLH—pancreatic cancer	0.000912	0.00301	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTCH1—pancreatic cancer	0.000912	0.00301	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000901	0.00298	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SSTR1—pancreatic cancer	0.0009	0.00297	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PPY—pancreatic cancer	0.000882	0.00291	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SSTR2—pancreatic cancer	0.000866	0.00286	CbGpPWpGaD
Degarelix—Vomiting—Tamoxifen—pancreatic cancer	0.000865	0.0013	CcSEcCtD
Degarelix—Cardiac failure—Doxorubicin—pancreatic cancer	0.000863	0.0013	CcSEcCtD
Degarelix—Hypotension—Fluorouracil—pancreatic cancer	0.000859	0.0013	CcSEcCtD
Degarelix—Hypersensitivity—Sunitinib—pancreatic cancer	0.000858	0.00129	CcSEcCtD
Degarelix—Rash—Tamoxifen—pancreatic cancer	0.000858	0.00129	CcSEcCtD
Degarelix—Dermatitis—Tamoxifen—pancreatic cancer	0.000857	0.00129	CcSEcCtD
Degarelix—Vomiting—Erlotinib—pancreatic cancer	0.000856	0.00129	CcSEcCtD
Degarelix—Dyspnoea—Irinotecan—pancreatic cancer	0.000855	0.00129	CcSEcCtD
Degarelix—Headache—Tamoxifen—pancreatic cancer	0.000852	0.00129	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000852	0.00128	CcSEcCtD
Degarelix—Rash—Erlotinib—pancreatic cancer	0.000848	0.00128	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CNR1—pancreatic cancer	0.000848	0.0028	CbGpPWpGaD
Degarelix—Dermatitis—Erlotinib—pancreatic cancer	0.000848	0.00128	CcSEcCtD
Degarelix—Angiopathy—Docetaxel—pancreatic cancer	0.000847	0.00128	CcSEcCtD
Degarelix—Insomnia—Gemcitabine—pancreatic cancer	0.000845	0.00128	CcSEcCtD
Degarelix—Immune system disorder—Docetaxel—pancreatic cancer	0.000843	0.00127	CcSEcCtD
Degarelix—Headache—Erlotinib—pancreatic cancer	0.000843	0.00127	CcSEcCtD
Degarelix—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000841	0.00127	CcSEcCtD
Degarelix—Chills—Docetaxel—pancreatic cancer	0.000838	0.00126	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000837	0.00126	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CCKBR—pancreatic cancer	0.000837	0.00276	CbGpPWpGaD
Degarelix—Asthenia—Sunitinib—pancreatic cancer	0.000836	0.00126	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—SST—pancreatic cancer	0.000835	0.00276	CbGpPWpGaD
Degarelix—Decreased appetite—Irinotecan—pancreatic cancer	0.000834	0.00126	CcSEcCtD
Degarelix—Arrhythmia—Docetaxel—pancreatic cancer	0.000834	0.00126	CcSEcCtD
Degarelix—Dyspnoea—Gemcitabine—pancreatic cancer	0.000833	0.00126	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000832	0.00275	CbGpPWpGaD
Degarelix—Insomnia—Fluorouracil—pancreatic cancer	0.000831	0.00125	CcSEcCtD
Degarelix—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000828	0.00125	CcSEcCtD
Degarelix—Fatigue—Irinotecan—pancreatic cancer	0.000827	0.00125	CcSEcCtD
Degarelix—Alopecia—Docetaxel—pancreatic cancer	0.000825	0.00124	CcSEcCtD
Degarelix—Pruritus—Sunitinib—pancreatic cancer	0.000824	0.00124	CcSEcCtD
Degarelix—Breast disorder—Epirubicin—pancreatic cancer	0.000823	0.00124	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000821	0.00271	CbGpPWpGaD
Degarelix—Pain—Irinotecan—pancreatic cancer	0.000821	0.00124	CcSEcCtD
Degarelix—Constipation—Irinotecan—pancreatic cancer	0.000821	0.00124	CcSEcCtD
Degarelix—Dyspnoea—Fluorouracil—pancreatic cancer	0.000819	0.00124	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—GCG—pancreatic cancer	0.000819	0.00271	CbGpPWpGaD
Degarelix—Mental disorder—Docetaxel—pancreatic cancer	0.000818	0.00123	CcSEcCtD
Degarelix—Erythema—Docetaxel—pancreatic cancer	0.000813	0.00123	CcSEcCtD
Degarelix—Malnutrition—Docetaxel—pancreatic cancer	0.000813	0.00123	CcSEcCtD
Degarelix—Decreased appetite—Gemcitabine—pancreatic cancer	0.000812	0.00123	CcSEcCtD
Degarelix—Nausea—Tamoxifen—pancreatic cancer	0.000808	0.00122	CcSEcCtD
Degarelix—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000807	0.00122	CcSEcCtD
Degarelix—Fatigue—Gemcitabine—pancreatic cancer	0.000806	0.00122	CcSEcCtD
Degarelix—Muscular weakness—Epirubicin—pancreatic cancer	0.000803	0.00121	CcSEcCtD
Degarelix—Pain—Gemcitabine—pancreatic cancer	0.000799	0.00121	CcSEcCtD
Degarelix—Constipation—Gemcitabine—pancreatic cancer	0.000799	0.00121	CcSEcCtD
Degarelix—Nausea—Erlotinib—pancreatic cancer	0.000799	0.00121	CcSEcCtD
Degarelix—Decreased appetite—Fluorouracil—pancreatic cancer	0.000799	0.00121	CcSEcCtD
Degarelix—Diarrhoea—Sunitinib—pancreatic cancer	0.000797	0.0012	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000797	0.00263	CbGpPWpGaD
Degarelix—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000793	0.0012	CcSEcCtD
Degarelix—Feeling abnormal—Irinotecan—pancreatic cancer	0.000791	0.00119	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GLI1—pancreatic cancer	0.000786	0.0026	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—DTX4—pancreatic cancer	0.000786	0.0026	CbGpPWpGaD
Degarelix—Back pain—Docetaxel—pancreatic cancer	0.000786	0.00119	CcSEcCtD
Degarelix—Pain—Fluorouracil—pancreatic cancer	0.000786	0.00119	CcSEcCtD
Degarelix—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000785	0.00118	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000781	0.00258	CbGpPWpGaD
Degarelix—Muscle spasms—Docetaxel—pancreatic cancer	0.000781	0.00118	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000776	0.00256	CbGpPWpGaD
Degarelix—Dizziness—Sunitinib—pancreatic cancer	0.00077	0.00116	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CNR1—pancreatic cancer	0.00077	0.00254	CbGpPWpGaD
Degarelix—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00077	0.00116	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NRP1—pancreatic cancer	0.000765	0.00253	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000765	0.00253	CbGpPWpGaD
Degarelix—Breast disorder—Doxorubicin—pancreatic cancer	0.000761	0.00115	CcSEcCtD
Degarelix—Abdominal pain—Irinotecan—pancreatic cancer	0.000759	0.00114	CcSEcCtD
Degarelix—Body temperature increased—Irinotecan—pancreatic cancer	0.000759	0.00114	CcSEcCtD
Degarelix—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000757	0.00114	CcSEcCtD
Degarelix—Anaemia—Docetaxel—pancreatic cancer	0.000751	0.00113	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—GCG—pancreatic cancer	0.000744	0.00246	CbGpPWpGaD
Degarelix—Muscular weakness—Doxorubicin—pancreatic cancer	0.000743	0.00112	CcSEcCtD
Degarelix—Vomiting—Sunitinib—pancreatic cancer	0.000741	0.00112	CcSEcCtD
Degarelix—Body temperature increased—Gemcitabine—pancreatic cancer	0.000739	0.00111	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HEY2—pancreatic cancer	0.000736	0.00243	CbGpPWpGaD
Degarelix—Dysuria—Epirubicin—pancreatic cancer	0.000736	0.00111	CcSEcCtD
Degarelix—Rash—Sunitinib—pancreatic cancer	0.000734	0.00111	CcSEcCtD
Degarelix—Dermatitis—Sunitinib—pancreatic cancer	0.000734	0.00111	CcSEcCtD
Degarelix—Urticaria—Fluorouracil—pancreatic cancer	0.00073	0.0011	CcSEcCtD
Degarelix—Headache—Sunitinib—pancreatic cancer	0.00073	0.0011	CcSEcCtD
Degarelix—Pollakiuria—Epirubicin—pancreatic cancer	0.000727	0.0011	CcSEcCtD
Degarelix—Body temperature increased—Fluorouracil—pancreatic cancer	0.000726	0.0011	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GAST—pancreatic cancer	0.000719	0.00238	CbGpPWpGaD
Degarelix—Palpitations—Docetaxel—pancreatic cancer	0.000718	0.00108	CcSEcCtD
Degarelix—Weight increased—Epirubicin—pancreatic cancer	0.000716	0.00108	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000713	0.00235	CbGpPWpGaD
Degarelix—Weight decreased—Epirubicin—pancreatic cancer	0.000712	0.00107	CcSEcCtD
Degarelix—Hyperglycaemia—Epirubicin—pancreatic cancer	0.00071	0.00107	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—AGTR1—pancreatic cancer	0.00071	0.00234	CbGpPWpGaD
Degarelix—Hypersensitivity—Irinotecan—pancreatic cancer	0.000707	0.00107	CcSEcCtD
Degarelix—Hypertension—Docetaxel—pancreatic cancer	0.000702	0.00106	CcSEcCtD
Degarelix—Arthralgia—Docetaxel—pancreatic cancer	0.000692	0.00104	CcSEcCtD
Degarelix—Nausea—Sunitinib—pancreatic cancer	0.000692	0.00104	CcSEcCtD
Degarelix—Renal failure—Epirubicin—pancreatic cancer	0.00069	0.00104	CcSEcCtD
Degarelix—Asthenia—Irinotecan—pancreatic cancer	0.000688	0.00104	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000687	0.00104	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HEY1—pancreatic cancer	0.000682	0.00225	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SCT—pancreatic cancer	0.000682	0.00225	CbGpPWpGaD
Degarelix—Urinary tract infection—Epirubicin—pancreatic cancer	0.000682	0.00103	CcSEcCtD
Degarelix—Dysuria—Doxorubicin—pancreatic cancer	0.000681	0.00103	CcSEcCtD
Degarelix—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000677	0.00102	CcSEcCtD
Degarelix—Dry mouth—Docetaxel—pancreatic cancer	0.000677	0.00102	CcSEcCtD
Degarelix—Pollakiuria—Doxorubicin—pancreatic cancer	0.000672	0.00101	CcSEcCtD
Degarelix—Asthenia—Gemcitabine—pancreatic cancer	0.000671	0.00101	CcSEcCtD
Degarelix—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000663	0.001	CcSEcCtD
Degarelix—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000663	0.001	CcSEcCtD
Degarelix—Weight increased—Doxorubicin—pancreatic cancer	0.000662	0.000999	CcSEcCtD
Degarelix—Pruritus—Gemcitabine—pancreatic cancer	0.000661	0.000997	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000659	0.00218	CbGpPWpGaD
Degarelix—Weight decreased—Doxorubicin—pancreatic cancer	0.000659	0.000993	CcSEcCtD
Degarelix—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000657	0.000991	CcSEcCtD
Degarelix—Diarrhoea—Irinotecan—pancreatic cancer	0.000656	0.00099	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CCK—pancreatic cancer	0.000651	0.00215	CbGpPWpGaD
Degarelix—Nervous system disorder—Docetaxel—pancreatic cancer	0.00065	0.000981	CcSEcCtD
Degarelix—Pruritus—Fluorouracil—pancreatic cancer	0.00065	0.000981	CcSEcCtD
Degarelix—Skin disorder—Docetaxel—pancreatic cancer	0.000644	0.000972	CcSEcCtD
Degarelix—Diarrhoea—Gemcitabine—pancreatic cancer	0.000639	0.000965	CcSEcCtD
Degarelix—Renal failure—Doxorubicin—pancreatic cancer	0.000638	0.000962	CcSEcCtD
Degarelix—Dizziness—Irinotecan—pancreatic cancer	0.000634	0.000957	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GLP1R—pancreatic cancer	0.000634	0.00209	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CNR2—pancreatic cancer	0.000634	0.00209	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL8—pancreatic cancer	0.000634	0.00209	CbGpPWpGaD
Degarelix—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000631	0.000952	CcSEcCtD
Degarelix—Diarrhoea—Fluorouracil—pancreatic cancer	0.000629	0.000948	CcSEcCtD
Degarelix—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000627	0.000945	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CCKAR—pancreatic cancer	0.000624	0.00206	CbGpPWpGaD
Degarelix—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000622	0.000938	CcSEcCtD
Degarelix—Oedema peripheral—Epirubicin—pancreatic cancer	0.00062	0.000936	CcSEcCtD
Degarelix—Hypotension—Docetaxel—pancreatic cancer	0.00062	0.000935	CcSEcCtD
Degarelix—Urethral disorder—Epirubicin—pancreatic cancer	0.000617	0.000931	CcSEcCtD
Degarelix—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000614	0.000926	CcSEcCtD
Degarelix—Vomiting—Irinotecan—pancreatic cancer	0.00061	0.00092	CcSEcCtD
Degarelix—Dizziness—Fluorouracil—pancreatic cancer	0.000608	0.000917	CcSEcCtD
Degarelix—Rash—Irinotecan—pancreatic cancer	0.000605	0.000913	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—JAG2—pancreatic cancer	0.000605	0.002	CbGpPWpGaD
Degarelix—Dermatitis—Irinotecan—pancreatic cancer	0.000604	0.000912	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000604	0.000912	CcSEcCtD
Degarelix—Headache—Irinotecan—pancreatic cancer	0.000601	0.000907	CcSEcCtD
Degarelix—Insomnia—Docetaxel—pancreatic cancer	0.0006	0.000905	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—MEN1—pancreatic cancer	0.000596	0.00197	CbGpPWpGaD
Degarelix—Vomiting—Gemcitabine—pancreatic cancer	0.000594	0.000896	CcSEcCtD
Degarelix—Dyspnoea—Docetaxel—pancreatic cancer	0.000591	0.000892	CcSEcCtD
Degarelix—Rash—Gemcitabine—pancreatic cancer	0.000589	0.000889	CcSEcCtD
Degarelix—Dermatitis—Gemcitabine—pancreatic cancer	0.000589	0.000888	CcSEcCtD
Degarelix—Eye disorder—Epirubicin—pancreatic cancer	0.000588	0.000888	CcSEcCtD
Degarelix—Headache—Gemcitabine—pancreatic cancer	0.000586	0.000883	CcSEcCtD
Degarelix—Cardiac disorder—Epirubicin—pancreatic cancer	0.000584	0.000882	CcSEcCtD
Degarelix—Vomiting—Fluorouracil—pancreatic cancer	0.000584	0.000881	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.00058	0.000874	CcSEcCtD
Degarelix—Rash—Fluorouracil—pancreatic cancer	0.000579	0.000874	CcSEcCtD
Degarelix—Dermatitis—Fluorouracil—pancreatic cancer	0.000579	0.000873	CcSEcCtD
Degarelix—Decreased appetite—Docetaxel—pancreatic cancer	0.000577	0.00087	CcSEcCtD
Degarelix—Headache—Fluorouracil—pancreatic cancer	0.000576	0.000868	CcSEcCtD
Degarelix—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000575	0.000868	CcSEcCtD
Degarelix—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000574	0.000866	CcSEcCtD
Degarelix—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000573	0.000864	CcSEcCtD
Degarelix—Fatigue—Docetaxel—pancreatic cancer	0.000572	0.000863	CcSEcCtD
Degarelix—Angiopathy—Epirubicin—pancreatic cancer	0.000571	0.000862	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—pancreatic cancer	0.000571	0.000862	CcSEcCtD
Degarelix—Nausea—Irinotecan—pancreatic cancer	0.00057	0.00086	CcSEcCtD
Degarelix—Immune system disorder—Epirubicin—pancreatic cancer	0.000569	0.000858	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—SHH—pancreatic cancer	0.000569	0.00188	CbGpPWpGaD
Degarelix—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000568	0.000856	CcSEcCtD
Degarelix—Pain—Docetaxel—pancreatic cancer	0.000567	0.000856	CcSEcCtD
Degarelix—Constipation—Docetaxel—pancreatic cancer	0.000567	0.000856	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NOTCH4—pancreatic cancer	0.000565	0.00187	CbGpPWpGaD
Degarelix—Chills—Epirubicin—pancreatic cancer	0.000565	0.000852	CcSEcCtD
Degarelix—Arrhythmia—Epirubicin—pancreatic cancer	0.000563	0.000849	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—IAPP—pancreatic cancer	0.000562	0.00185	CbGpPWpGaD
Degarelix—Alopecia—Epirubicin—pancreatic cancer	0.000556	0.000839	CcSEcCtD
Degarelix—Nausea—Gemcitabine—pancreatic cancer	0.000555	0.000837	CcSEcCtD
Degarelix—Mental disorder—Epirubicin—pancreatic cancer	0.000552	0.000832	CcSEcCtD
Degarelix—Malnutrition—Epirubicin—pancreatic cancer	0.000548	0.000827	CcSEcCtD
Degarelix—Erythema—Epirubicin—pancreatic cancer	0.000548	0.000827	CcSEcCtD
Degarelix—Feeling abnormal—Docetaxel—pancreatic cancer	0.000547	0.000824	CcSEcCtD
Degarelix—Nausea—Fluorouracil—pancreatic cancer	0.000546	0.000823	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—pancreatic cancer	0.000545	0.000821	CcSEcCtD
Degarelix—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000542	0.000818	CcSEcCtD
Degarelix—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000541	0.000816	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PTHLH—pancreatic cancer	0.000539	0.00178	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTCH1—pancreatic cancer	0.000539	0.00178	CbGpPWpGaD
Degarelix—Back pain—Epirubicin—pancreatic cancer	0.00053	0.0008	CcSEcCtD
Degarelix—Angiopathy—Doxorubicin—pancreatic cancer	0.000529	0.000797	CcSEcCtD
Degarelix—Muscle spasms—Epirubicin—pancreatic cancer	0.000527	0.000795	CcSEcCtD
Degarelix—Immune system disorder—Doxorubicin—pancreatic cancer	0.000526	0.000794	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000525	0.000792	CcSEcCtD
Degarelix—Abdominal pain—Docetaxel—pancreatic cancer	0.000524	0.000791	CcSEcCtD
Degarelix—Body temperature increased—Docetaxel—pancreatic cancer	0.000524	0.000791	CcSEcCtD
Degarelix—Chills—Doxorubicin—pancreatic cancer	0.000523	0.000789	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—pancreatic cancer	0.000521	0.000785	CcSEcCtD
Degarelix—Vision blurred—Epirubicin—pancreatic cancer	0.000517	0.000779	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—pancreatic cancer	0.000515	0.000777	CcSEcCtD
Degarelix—Mental disorder—Doxorubicin—pancreatic cancer	0.00051	0.00077	CcSEcCtD
Degarelix—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000509	0.000767	CcSEcCtD
Degarelix—Erythema—Doxorubicin—pancreatic cancer	0.000507	0.000765	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—pancreatic cancer	0.000507	0.000765	CcSEcCtD
Degarelix—Anaemia—Epirubicin—pancreatic cancer	0.000507	0.000764	CcSEcCtD
Degarelix—Malaise—Epirubicin—pancreatic cancer	0.000494	0.000746	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—SST—pancreatic cancer	0.000493	0.00163	CbGpPWpGaD
Degarelix—Back pain—Doxorubicin—pancreatic cancer	0.000491	0.00074	CcSEcCtD
Degarelix—Hypersensitivity—Docetaxel—pancreatic cancer	0.000489	0.000737	CcSEcCtD
Degarelix—Muscle spasms—Doxorubicin—pancreatic cancer	0.000488	0.000736	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000486	0.00161	CbGpPWpGaD
Degarelix—Palpitations—Epirubicin—pancreatic cancer	0.000484	0.000731	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—JAG1—pancreatic cancer	0.000482	0.00159	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NOTCH3—pancreatic cancer	0.00048	0.00159	CbGpPWpGaD
Degarelix—Vision blurred—Doxorubicin—pancreatic cancer	0.000478	0.000721	CcSEcCtD
Degarelix—Asthenia—Docetaxel—pancreatic cancer	0.000476	0.000718	CcSEcCtD
Degarelix—Hypertension—Epirubicin—pancreatic cancer	0.000473	0.000714	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000471	0.00071	CcSEcCtD
Degarelix—Pruritus—Docetaxel—pancreatic cancer	0.000469	0.000708	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—pancreatic cancer	0.000469	0.000707	CcSEcCtD
Degarelix—Arthralgia—Epirubicin—pancreatic cancer	0.000467	0.000704	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000463	0.000699	CcSEcCtD
Degarelix—Discomfort—Epirubicin—pancreatic cancer	0.000461	0.000696	CcSEcCtD
Degarelix—Malaise—Doxorubicin—pancreatic cancer	0.000457	0.00069	CcSEcCtD
Degarelix—Dry mouth—Epirubicin—pancreatic cancer	0.000456	0.000688	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CNR1—pancreatic cancer	0.000455	0.0015	CbGpPWpGaD
Degarelix—Diarrhoea—Docetaxel—pancreatic cancer	0.000454	0.000685	CcSEcCtD
Degarelix—Palpitations—Doxorubicin—pancreatic cancer	0.000448	0.000676	CcSEcCtD
Degarelix—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000447	0.000675	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000442	0.00146	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GCG—pancreatic cancer	0.000439	0.00145	CbGpPWpGaD
Degarelix—Nervous system disorder—Epirubicin—pancreatic cancer	0.000439	0.000662	CcSEcCtD
Degarelix—Dizziness—Docetaxel—pancreatic cancer	0.000439	0.000662	CcSEcCtD
Degarelix—Hypertension—Doxorubicin—pancreatic cancer	0.000438	0.000661	CcSEcCtD
Degarelix—Skin disorder—Epirubicin—pancreatic cancer	0.000435	0.000656	CcSEcCtD
Degarelix—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000432	0.000652	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—pancreatic cancer	0.000432	0.000651	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000429	0.000647	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000427	0.00141	CbGpPWpGaD
Degarelix—Discomfort—Doxorubicin—pancreatic cancer	0.000427	0.000644	CcSEcCtD
Degarelix—Dry mouth—Doxorubicin—pancreatic cancer	0.000422	0.000637	CcSEcCtD
Degarelix—Vomiting—Docetaxel—pancreatic cancer	0.000422	0.000636	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—AGTR1—pancreatic cancer	0.000419	0.00138	CbGpPWpGaD
Degarelix—Rash—Docetaxel—pancreatic cancer	0.000418	0.000631	CcSEcCtD
Degarelix—Hypotension—Epirubicin—pancreatic cancer	0.000418	0.000631	CcSEcCtD
Degarelix—Dermatitis—Docetaxel—pancreatic cancer	0.000418	0.00063	CcSEcCtD
Degarelix—Headache—Docetaxel—pancreatic cancer	0.000416	0.000627	CcSEcCtD
Degarelix—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000414	0.000624	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—STK11—pancreatic cancer	0.000413	0.00136	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000408	0.000615	CcSEcCtD
Degarelix—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000406	0.000612	CcSEcCtD
Degarelix—Insomnia—Epirubicin—pancreatic cancer	0.000405	0.00061	CcSEcCtD
Degarelix—Skin disorder—Doxorubicin—pancreatic cancer	0.000402	0.000607	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.0004	0.000604	CcSEcCtD
Degarelix—Dyspnoea—Epirubicin—pancreatic cancer	0.000399	0.000602	CcSEcCtD
Degarelix—Nausea—Docetaxel—pancreatic cancer	0.000394	0.000594	CcSEcCtD
Degarelix—Decreased appetite—Epirubicin—pancreatic cancer	0.000389	0.000587	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000388	0.00128	CbGpPWpGaD
Degarelix—Hypotension—Doxorubicin—pancreatic cancer	0.000387	0.000583	CcSEcCtD
Degarelix—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000386	0.000583	CcSEcCtD
Degarelix—Fatigue—Epirubicin—pancreatic cancer	0.000386	0.000582	CcSEcCtD
Degarelix—Pain—Epirubicin—pancreatic cancer	0.000383	0.000577	CcSEcCtD
Degarelix—Constipation—Epirubicin—pancreatic cancer	0.000383	0.000577	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000377	0.000569	CcSEcCtD
Degarelix—Insomnia—Doxorubicin—pancreatic cancer	0.000374	0.000565	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000373	0.00123	CbGpPWpGaD
Degarelix—Dyspnoea—Doxorubicin—pancreatic cancer	0.000369	0.000557	CcSEcCtD
Degarelix—Feeling abnormal—Epirubicin—pancreatic cancer	0.000369	0.000556	CcSEcCtD
Degarelix—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000366	0.000552	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—SMAD4—pancreatic cancer	0.000362	0.0012	CbGpPWpGaD
Degarelix—Decreased appetite—Doxorubicin—pancreatic cancer	0.00036	0.000543	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000358	0.00118	CbGpPWpGaD
Degarelix—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000357	0.000539	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—pancreatic cancer	0.000357	0.000538	CcSEcCtD
Degarelix—Urticaria—Epirubicin—pancreatic cancer	0.000355	0.000536	CcSEcCtD
Degarelix—Constipation—Doxorubicin—pancreatic cancer	0.000354	0.000534	CcSEcCtD
Degarelix—Pain—Doxorubicin—pancreatic cancer	0.000354	0.000534	CcSEcCtD
Degarelix—Body temperature increased—Epirubicin—pancreatic cancer	0.000354	0.000533	CcSEcCtD
Degarelix—Abdominal pain—Epirubicin—pancreatic cancer	0.000354	0.000533	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HES1—pancreatic cancer	0.000353	0.00117	CbGpPWpGaD
Degarelix—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000341	0.000515	CcSEcCtD
Degarelix—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000338	0.000511	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000338	0.00112	CbGpPWpGaD
Degarelix—Hypersensitivity—Epirubicin—pancreatic cancer	0.00033	0.000497	CcSEcCtD
Degarelix—Urticaria—Doxorubicin—pancreatic cancer	0.000329	0.000496	CcSEcCtD
Degarelix—Body temperature increased—Doxorubicin—pancreatic cancer	0.000327	0.000494	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—pancreatic cancer	0.000327	0.000494	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CXCL8—pancreatic cancer	0.000325	0.00107	CbGpPWpGaD
Degarelix—Asthenia—Epirubicin—pancreatic cancer	0.000321	0.000484	CcSEcCtD
Degarelix—Pruritus—Epirubicin—pancreatic cancer	0.000317	0.000477	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TERT—pancreatic cancer	0.00031	0.00102	CbGpPWpGaD
Degarelix—Diarrhoea—Epirubicin—pancreatic cancer	0.000306	0.000462	CcSEcCtD
Degarelix—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000305	0.00046	CcSEcCtD
Degarelix—Asthenia—Doxorubicin—pancreatic cancer	0.000297	0.000448	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HIF1A—pancreatic cancer	0.000296	0.000978	CbGpPWpGaD
Degarelix—Dizziness—Epirubicin—pancreatic cancer	0.000296	0.000446	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TSC2—pancreatic cancer	0.000295	0.000975	CbGpPWpGaD
Degarelix—Pruritus—Doxorubicin—pancreatic cancer	0.000293	0.000442	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—APOE—pancreatic cancer	0.000289	0.000955	CbGpPWpGaD
Degarelix—Vomiting—Epirubicin—pancreatic cancer	0.000284	0.000429	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—pancreatic cancer	0.000283	0.000427	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—KDR—pancreatic cancer	0.000283	0.000935	CbGpPWpGaD
Degarelix—Rash—Epirubicin—pancreatic cancer	0.000282	0.000426	CcSEcCtD
Degarelix—Dermatitis—Epirubicin—pancreatic cancer	0.000282	0.000425	CcSEcCtD
Degarelix—Headache—Epirubicin—pancreatic cancer	0.00028	0.000423	CcSEcCtD
Degarelix—Dizziness—Doxorubicin—pancreatic cancer	0.000274	0.000413	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NFKBIA—pancreatic cancer	0.000269	0.000889	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NOTCH1—pancreatic cancer	0.000267	0.000881	CbGpPWpGaD
Degarelix—Nausea—Epirubicin—pancreatic cancer	0.000266	0.000401	CcSEcCtD
Degarelix—Vomiting—Doxorubicin—pancreatic cancer	0.000263	0.000397	CcSEcCtD
Degarelix—Rash—Doxorubicin—pancreatic cancer	0.000261	0.000394	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PIK3CG—pancreatic cancer	0.000261	0.000861	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—NRAS—pancreatic cancer	0.000261	0.000861	CbGpPWpGaD
Degarelix—Dermatitis—Doxorubicin—pancreatic cancer	0.000261	0.000393	CcSEcCtD
Degarelix—Headache—Doxorubicin—pancreatic cancer	0.000259	0.000391	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—EGF—pancreatic cancer	0.000258	0.000852	CbGpPWpGaD
Degarelix—Nausea—Doxorubicin—pancreatic cancer	0.000246	0.000371	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—EGFR—pancreatic cancer	0.000238	0.000785	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CD—pancreatic cancer	0.000229	0.000757	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.000227	0.00075	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KRAS—pancreatic cancer	0.000225	0.000741	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000206	0.000681	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CB—pancreatic cancer	0.0002	0.00066	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL8—pancreatic cancer	0.000192	0.000634	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—HRAS—pancreatic cancer	0.000191	0.00063	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT1—pancreatic cancer	0.000186	0.000613	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CASP3—pancreatic cancer	0.000184	0.000607	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCND1—pancreatic cancer	0.000179	0.000591	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CTNNB1—pancreatic cancer	0.000177	0.000585	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP9—pancreatic cancer	0.000174	0.000574	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTEN—pancreatic cancer	0.000173	0.00057	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT1—pancreatic cancer	0.000168	0.000556	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SRC—pancreatic cancer	0.00016	0.000529	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFA—pancreatic cancer	0.000156	0.000515	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT3—pancreatic cancer	0.000154	0.00051	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NRAS—pancreatic cancer	0.000154	0.000509	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MYC—pancreatic cancer	0.000144	0.000474	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TGFB1—pancreatic cancer	0.000143	0.000473	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGFR—pancreatic cancer	0.00014	0.000464	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KRAS—pancreatic cancer	0.000133	0.000438	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CA—pancreatic cancer	0.000122	0.000402	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TP53—pancreatic cancer	0.000118	0.000389	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRAS—pancreatic cancer	0.000113	0.000372	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT1—pancreatic cancer	9.95e-05	0.000329	CbGpPWpGaD
